Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,963.00
Ask: 1,965.00
Change: -36.00 (-1.81%)
Spread: 2.00 (0.102%)
Open: 2,004.00
High: 2,004.00
Low: 1,958.00
Prev. Close: 1,994.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hikma Pharmaceuticals Guides For Growth In 2016 As Profit Falls

Wed, 16th Mar 2016 07:24

LONDON (Alliance News) - Hikma Pharmaceuticals PLC on Wednesday reported a fall in pretax profit in 2015, but forecast a significant rise in revenue for the year ahead, helped by its recent acquisition of the Roxane Laboratories Inc, despite lowering its guidance for the Roxane business last month.

The company reported a pretax profit of USD318 million, down from USD362 million in 2014, as revenue slipped to USD1.44 billion from USD1.49 billion the year before.

Analysts had expected Hikma to report a pretax profit of USD302.2 million on revenue of USD1.44 billion, so it beat expectations for profit and met them for revenue.

The fall in revenue was primarily as a result of a decline in Hikma's Generics business due to increased competition, in line with the company's most recent guidance, which was down 30% to USD151 million in 2015 from USD216 million in 2014.

Hikma proposed a final dividend of 21 cents per share, taking its total dividend to 32 cents for the year, in line with what it paid in 2014.

Looking ahead, the company said it expects to see revenue in 2016 in the range of USD2.0 billion to USD2.1 billion at constant currency, driven by strong growth from all three of its business segments and boosted by ten months of revenue from the Roxane business.

This is despite expecting Roxane's full-year revenue in 2016 to be below USD650 million, although Hikma expects this to increase to USD700 million to USD750 million in 2017.

"The integration of the acquisition of Roxane, which closed at the end of February, will be a key focus this year and will transform our non-injectables business in the US, adding complementary and well differentiated products, an attractive pipeline, proven R&D capabilities and greater overall scale," said Chairman and Chief Executive Said Darwazah in a statement.

"From 2017, we expect the benefits from the investments that we have made in recent years - in R&D, M&A, co-development partnerships and licensing agreements - to accelerate. We have an exciting pipeline across our business segments that will drive accelerated and sustainable future growth," Darwazah added.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
12 Aug 2021 16:04

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
6 Aug 2021 17:06

LONDON MARKET CLOSE: FTSE 100 boosted by strong US jobs report

LONDON MARKET CLOSE: FTSE 100 boosted by strong US jobs report

Read more
6 Aug 2021 12:07

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

Read more
6 Aug 2021 09:03

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

Read more
6 Aug 2021 08:40

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

Read more
6 Aug 2021 07:42

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

Read more
6 Aug 2021 07:22

Hikma lifts FY generics guidance as first-half profits, revenue jump

(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.

Read more
30 Jul 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
14 Jul 2021 19:38

IN BRIEF: Arecor ends first half of 2021 with solid cash position

IN BRIEF: Arecor ends first half of 2021 with solid cash position

Read more
13 Jul 2021 10:00

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

Read more
1 Jul 2021 09:51

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

Read more
21 Jun 2021 14:51

UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...

Read more
21 Jun 2021 14:31

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...

Read more
8 Jun 2021 13:54

Tuesday broker round-up

(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.

Read more
6 May 2021 09:46

BROKER RATINGS: Exane BNP downgrades three property companies

BROKER RATINGS: Exane BNP downgrades three property companies

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.